KNSA (Kiniksa Pharmaceuticals) חוב לטווח קצר להון

Kiniksa Pharmaceuticals (KNSA) monetizes therapies for rare inflammatory processes, leveraging patent protection and consistent demand. The market trend for the stock price reflects the value of 0.00. Business revenues are based on the sale of ARCALYST for the treatment of autoimmune pathologies. Meanwhile, Kiniksa Pharmaceuticals (KNSA) is optimizing raw material procurement to eliminate supply chain disruptions and ensure the continuous production of medications.

This ratio determines the extent of the company's dependence on short-term liabilities relative to its equity, measuring liquidity risk and the level of financial leverage. By analyzing the short-term debt-to-equity ratio on the GURU.Markets platform, an investor assesses the ability of Kiniksa Pharmaceuticals (KNSA) to finance laboratory robotization and the implementation of drug distribution software without incurring a critical debt burden.